石新丽，女，1976年出生，毕业于四川大学。免疫学博士，教授，博士生/硕士生导师，国家中医药管理局重点学科（中西医结合基础）的学术带头人，山西省重点实验室中西医结合肿瘤免疫学重点研究室和山西省中医药管理局中西医结合肿瘤免疫学研究中医药创新团队负责人。曾入选河北省“三三三人才工程”第二层次、山西中医药大学“杏林英才”计划人选（科技创新领军人才）、评为2021/2022学年河北省优秀硕士学位论文指导教师。2023年，作为高层次人才全职引进到山西中医药大学工作。先后主持省部级以上课题10项，其中连续主持2项国家自然科学基金面上项目（81873112、82274315），发表文章60余篇，其中SCI杂志收录文章46篇（一作/通讯38篇；中科院1区6篇，2区13篇），出版专著1 部（主编）；授权并已转化国家发明专利1项。兼任中国中医药信息学会科技创新与成果转化分会常务理事（2021.06-2026.06）、中国民族医药学会药理与毒理学分会理事（2019.12-2027.12）、中华中医药学会肿瘤分会第七届委员（2024.06-2028.06）、《医药导报》青年编委（2022.10-2026.10）、《遵义医科大学学报》编委（2025.06-今）、《中国免疫学杂志》等国内外多种杂志的特约审稿专家。已培养研究生26人（其中，毕业博士4人、硕士10人；在读硕士生12人）。
研究学科（领域）：中西医结合基础
研究方向：中医药抗肿瘤免疫调控机制；中医药改善肝病调控的机制
科研项目：
1.国家自然科学基金面上项目，82274315，2023.01-2026.12, 52万元，在研，主持。
2.山西省中医药科技创新工程项目，2025kjzy010，2025.01-2027.12，100万，主持，在研。
3.山西省中医药创新团队项目，zyytd2024021，2024.3-2027.3，30万，主持，在研。
4.山西省重点实验室建设项目，zyyyjs2024035，2024.3-2027.3，30万，主持，在研。
5.山西中医药大学高层次人才引进项目，中医药抗肿瘤免疫学机制研究， 2023RC03，2023.07-2028.07，300万，主持，在研。
6.山西中医药大学，2024 年度科技创新能力培育计划产学研合作引导专项资助项目，2024PY-CXY-012，2024.09-2026.08，12万，主持，在研。
代表性成果：
1.Shenghao Li#, Jingmin Ji#, Zhiqin Zhang, Qing Peng, Liyuan Hao, Yinglin Guo, Wenhan Zhou, Qingzhuo Cui, Xinli Shi*, Cisplatin promotes the expression level of PD-L1 in the microenvironment of hepatocellular carcinoma through YAP1,Molecular and Cellular Biochemistry, 2020, 475(1), 79-91.
2.Liyuan Hao, Yinglin Guo, Qing Peng, Zhiqin Zhang, Jingmin Ji, Yiwei Liu, Yu Xue, Caige Li, Kangning Zheng, Xinli Shi*，Dihydroartemisinin reduced lipid droplet deposition by YAP1 to promote the anti-PD-1 effect in hepatocellular carcinoma, Phytomedicine,2022,96:153913.
3.Yinglin Guo, Qing Peng, Liyuan Hao, Jingmin Ji, Zhiqin Zhang, Yu Xue, Yiwei Liu, Yuting Gao, Caige Li, Xinli Shi*,Dihydroartemisinin promoted FXR expression independent of YAP1 in hepatocellular carcinoma, FASEB Journal, 2022, 36(6):e22361.
4.Qing Peng, Liyuan Hao, Yinglin Guo, Zhiqin Zhang, Jingmin Ji, Yu Xue, Yiwei Liu, Junlan Lu, Caige Li, Xinli Shi*, Solute carrier family 2 members 1 and 2 as prognostic biomarkers in hepatocellular carcinoma associated with immune infiltration. World J Clin Cases, 2022,10(13): 3989-4019. (约稿)
5.Qing Peng#, Shenghao Li#, Xinli Shi*, Yinglin Guo, Liyuan Hao, Zhiqin Zhang, Jingmin Ji, Yanmeng Zhao, Caige Li, Yu Xue, Yiwei Liu，Dihydroartemisinin broke the tumor immunosuppressive microenvironment by inhibiting YAP1 expression to enhance anti-PD-1 efficacy, Phytotherapy Research,2023,37(5):1740-1753.
6.Zhiqin Zhang#, Xinli Shi*, Jingmin Ji#, Yinglin Guo, Qing Peng, Liyuan Hao, Yu Xue, Yiwei Liu, Caige Li, Junlan Lu, Kun Yu，Dihydroartemisinin increased the abundance of Akkermansia muciniphila by YAP1 depression that sensitizes hepatocellular carcinoma to anti-PD-1 immunotherapy，Frontiers of Medicine，2023，17(4):729-746.
7.Yiwei Liu#, Yu Xue#, Zhiqin Zhang, Jingmin Ji, Caige Li, Kangning Zheng, Junlan Lu, Yuting Gao, Yi Gong, Yuman Zhang, Xinli Shi*,Wolfberry enhanced the abundance of Akkermansia muciniphila by YAP1 in mice with acetaminophen-induced liver injury, FASEB Journal. 2023,37(1):e22689.
8.Qing Peng, Liyuan Hao, Yinglin Guo, Zhiqin Zhang, Jingmin Ji, Yu Xue, Yiwei Liu, Caige Li, Junlan Lu, Xinli Shi*, Dihydroartemisinin inhibited the Warburg effect through YAP1/SLC2A1 pathway in hepatocellular carcinoma, Journal of Natural Medicines,2023,77(1):28-40.
9.Yuting Gao#, Qing Peng#, Shenghao Li, Kangning Zheng, Yi Gong, Yu Xue, Yiwei Liu, Junlan Lu, Yuman Zhang, Xinli Shi*,YAP1 suppression inhibits autophagy and improves the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma，Experimental Cell Research, 2023, 424(1):113486.
10.Junlan Lu, Yi Gong, Yuting Gao, Yanguang Yang, Yuman Zhang, Zhiqin Zhang, Xinli Shi*, Wolfberry, Yam, and Chrysanthemum polysaccharides increased intestinal Akkermansia muciniphila abundance and hepatic YAP1 expression to alleviate DILI，FASEB Journal，2023，37(12):e23286.
11.Yuting Gao# , Yi Gong#, Junlan Lu, Yanguang Yang, Yuman Zhang, Yajun Xiong, Xinli Shi*，Dihydroartemisinin breaks the positive feedback loop of YAP1 and GLUT1-mediated aerobic glycolysis to boost the CD8+ effector T cells in hepatocellular carcinoma，Biochemical Pharmacology，2024, 116294.
12.Junlan Lu, Yuting Gao, Yi Gong, Yuan Yue, Yanguang Yang, Yajun Xiong, Yuman Zhang, Yan Xiao, Haodong Wang, Haibo Fan, Xinli Shi*，Lycium barbarum L. balanced intestinal flora with YAP1/FXR activation in drug-induced liver injury，International Immunopharmacology，2024，130 ：111762.
13.Yuting Gao#, Yi Gong#, Junlan Lu#, Huiqin Hao*, Xinli Shi*, Targeting YAP1 to improve the efficacy of immune checkpoint inhibitors in liver cancer: mechanism and strategy，Frontiers in Immunology，2024，15:1377722.
14.Yanguang Yang#, Yuting Gao#, Yajun Xiong#, Yi Gong, Junlan Lu, Yuman Zhang, Dan Wang, Zhihan Liu, Xinli Shi*,Research progress of Warburg effect in Hepatocellular Carcinoma,Frontiers in Bioscience-Landmark, 2024, 29(5), 178. (约稿)
15.Yanguang Yang, Shenghao Li, Qing Peng, Yinglin Guo, Yuting Gao, Yi Gong, Junlan Lu, Yuman Zhang, Xinli Shi *,Human umbilical cord mesenchymal stem cells promoted tumor cell growth associated with increased interleukin-18 in hepatocellular carcinoma，Molecular Biology Reports，2024，51(1):762.
16.Yanguang Yang, Yuting Gao, Yi Gong, Junlan Lu, Shenghao Li, Yajun Xiong, Yuman Zhang, Dan Wang, Peng Gong, Yunfeng Li *, Xinli Shi*，Dihydroartemisinin breaks the immunosuppressive tumor niche during cisplatin treatment in Hepatocellular carcinoma， Acta Histochemica，2024，126，152171.
17.Yanguang Yang，Xinli Shi*, Big lessons from the little Akkermansia muciniphila in hepatocellular carcinoma，Frontiers in Immunology. 2025, 16:1524563. (约稿)
18. Yi Gong, Yajun Xiong,Yuting Gao, Xiaoyong Song, Yanli Gong, Dan Wang, Zhihan Liu,Yanguang Yang, Junlan Lu, Isabelle Xinyue Zou, Xinli Shi*，Verteporfin inhibits the cGAS-STING pathway and improves the tumor microenvironment during cisplatin treatment in hepatocellular carcinoma, Frontiers in Immunology，2025, 16:1658042.
联系方式：
办公电话：0351-3179745
Email：sxlsunshine@sina.com
